Nothing Special   »   [go: up one dir, main page]

WO2000078266A3 - Interferon tau mutants and methods for making them - Google Patents

Interferon tau mutants and methods for making them Download PDF

Info

Publication number
WO2000078266A3
WO2000078266A3 PCT/IB2000/001080 IB0001080W WO0078266A3 WO 2000078266 A3 WO2000078266 A3 WO 2000078266A3 IB 0001080 W IB0001080 W IB 0001080W WO 0078266 A3 WO0078266 A3 WO 0078266A3
Authority
WO
WIPO (PCT)
Prior art keywords
ifn
making
mutants
tau
directed
Prior art date
Application number
PCT/IB2000/001080
Other languages
French (fr)
Other versions
WO2000078266A2 (en
Inventor
Carol H Pontzer
Lynnette H Shorts
Christina Dancz Clark
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Priority to AU61758/00A priority Critical patent/AU6175800A/en
Priority to JP2001504334A priority patent/JP2003525592A/en
Priority to CA002382425A priority patent/CA2382425A1/en
Priority to EP00948197A priority patent/EP1156771A2/en
Publication of WO2000078266A2 publication Critical patent/WO2000078266A2/en
Publication of WO2000078266A3 publication Critical patent/WO2000078266A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention is directed to the field of animal and human health, and more particularly to pharmacological uses of analogs or mutants of interferon-tau (IFN-τ) that differ from native IFN-τ because of substitutions of amino acids near the amino terminus of the IFN-τ molecule that impart improved biological activity. The IFN-τ mutants described in this disclosure have low toxicity, retain the same or slightly reduced antiviral activity compared with highly effective IFN-alpha, and have enhanced antiproliferative activity compared to native IFN-tau, making them useful in treating viral infections, cancer, and immune system diseases including autoimmune diseases. The present invention is also directed to a method for making novel recombinant proteins, especially interferons, interleukins, and cytokines, polypeptide hormones and other biopharmaceuticals that have improved biological activity over known proteins and/or lower toxicity and/or increased stability.
PCT/IB2000/001080 1999-06-22 2000-06-22 Interferon tau mutants and methods for making them WO2000078266A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU61758/00A AU6175800A (en) 1999-06-22 2000-06-22 Interferon tau mutants and methods for making them
JP2001504334A JP2003525592A (en) 1999-06-22 2000-06-22 Interferon tau mutant and method for producing the same
CA002382425A CA2382425A1 (en) 1999-06-22 2000-06-22 Interferon tau mutants and methods for making them
EP00948197A EP1156771A2 (en) 1999-06-22 2000-06-22 Interferon tau mutants and methods for making them

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14041199P 1999-06-22 1999-06-22
US60/140,411 1999-06-22

Publications (2)

Publication Number Publication Date
WO2000078266A2 WO2000078266A2 (en) 2000-12-28
WO2000078266A3 true WO2000078266A3 (en) 2001-08-23

Family

ID=22491109

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2000/001080 WO2000078266A2 (en) 1999-06-22 2000-06-22 Interferon tau mutants and methods for making them

Country Status (5)

Country Link
EP (1) EP1156771A2 (en)
JP (1) JP2003525592A (en)
AU (1) AU6175800A (en)
CA (1) CA2382425A1 (en)
WO (1) WO2000078266A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006213597A (en) 2000-07-19 2006-08-17 Pepgen Corp Composition for treating hepatitis c virus by using interferon tau and method of monitoring
US7083782B2 (en) 2000-07-19 2006-08-01 Pepgen Corporation Method of treatment using interferon-tau
US7105154B2 (en) 2000-07-19 2006-09-12 Pepgen Corporation Method of treatment using interferon-tau
WO2002006343A2 (en) * 2000-07-19 2002-01-24 Pepgen Corporation Composition for treatment of and method of monitoring hepatitis c virus using interferon-tau
US20040126360A1 (en) * 2002-10-09 2004-07-01 Manning Mark C. Oral formulations for proteins and polypeptides
US20060134750A1 (en) * 2004-03-10 2006-06-22 Pepgen Corporation Method of treatment using interferon-tau
WO2007018846A2 (en) * 2005-07-27 2007-02-15 Pepgen Coporation Use of interferon- tau for reduction of scar tissue formation
WO2007098106A2 (en) * 2006-02-17 2007-08-30 Pepgen Coporation Respiratory tract delivery of interferon-tau
FR2905375A1 (en) * 2006-08-29 2008-03-07 Biomethodes Sa Thermostable variants of human interferon alpha useful for preparing antiviral, antiproliferative or immunomodulatory medicaments have one or more selected amino acid substitutions
CN103965347B (en) 2007-05-02 2017-07-18 Ambrx公司 Modified interferon beta polypeptides and its purposes
CN108840921B (en) * 2018-05-31 2021-06-29 浙江善测禾骑士生物科技有限公司 Sheep alpha interferon mutant and preparation method and application thereof
RU2739261C1 (en) * 2019-12-31 2020-12-22 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Method for quantitative determination of anti-proliferative activity of human interferon-beta
CN115968291A (en) * 2020-04-22 2023-04-14 南湖制药公司 Pegylated interferon TAU and compositions and methods thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010313A2 (en) * 1992-10-30 1994-05-11 University Of Florida Interferon tau compositions and methods of use
WO1997033607A1 (en) * 1996-03-15 1997-09-18 University Of Florida Orally-administered interferon-tau compositions and methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010313A2 (en) * 1992-10-30 1994-05-11 University Of Florida Interferon tau compositions and methods of use
WO1997033607A1 (en) * 1996-03-15 1997-09-18 University Of Florida Orally-administered interferon-tau compositions and methods

Also Published As

Publication number Publication date
WO2000078266A2 (en) 2000-12-28
EP1156771A2 (en) 2001-11-28
AU6175800A (en) 2001-01-09
CA2382425A1 (en) 2000-12-28
JP2003525592A (en) 2003-09-02

Similar Documents

Publication Publication Date Title
WO2000078266A3 (en) Interferon tau mutants and methods for making them
Pestka et al. [1] Definition and classification of the interferons
Rinderknecht et al. Natural human interferon-gamma. Complete amino acid sequence and determination of sites of glycosylation.
US5723121A (en) Sugar modified interferon
NYMAN et al. Identification of nine interferon-α subtypes produced by Sendai virus-induced human peripheral blood leucocytes
Ceaglio et al. Novel long-lasting interferon alpha derivatives designed by glycoengineering
Zoon et al. Purification and characterization of multiple components of human lymphoblastoid interferon-alpha.
FI844934L (en) Process for Preparation of Recombinant Gamma Interferon with Improved Stability Vector and DNA Used in the Process
WO1993016107A1 (en) Improved alpha interferon composition and method for its production from human peripheral blood leukocytes
ATE402957T1 (en) LOW TOXICITY ANALOGUE OF HUMAN INTERFERON ALPHA
NZ233974A (en) Peptide inhibitors of human leucocyte elastases, recombinant production and compositions
US7083782B2 (en) Method of treatment using interferon-tau
US5789551A (en) Human leukocyte interferon Hu-IFN-α001
EA200000685A1 (en) COMPLEX IFNAR2 / IFN
WO2003016472A3 (en) Hybrid interferon/interferon tau proteins, compositions and methods of use
WO2002086087A3 (en) Cytokine protein family
Ando et al. Natural human interferon‐γ derived from lipopolysaccharide‐stimulated human myelomonocytic HBL‐38 cells
CN1902224B (en) Process for purifying interferon beta
HONDA et al. Differential purification by immunoaffinity chromatography of two carboxy-terminal portion-deleted derivatives of recombinant human interferon-γ from Escherichia coli
MATSUDA et al. Purification and characterization of recombinant mouse interferon-β
WO2021233094A1 (en) INTERFERON-κ MUTANT AND PREPARATION METHOD THEREFOR
DIPAOLA et al. Interferon-α2 produced by normal human leukocytes is predominantly interferon-α2b
ZOON et al. Human Leukocyte-derived Alpha-Interferons: Purification and Amino-terminal–Amino-Acid Sequence of Two Components
WO2019237079A3 (en) Pharmaceutical composition containing fusion protein and use thereof
US7780960B2 (en) Process for purifying interferon beta

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2000948197

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 61758/00

Country of ref document: AU

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000948197

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2382425

Country of ref document: CA

WWW Wipo information: withdrawn in national office

Ref document number: 2000948197

Country of ref document: EP